Regeneron: Driven by Science

For over 25 years, Regeneron's vision has been to build an innovative company that consistently brings new medicines to patients with serious diseases.

Recent News

Regeneron Announces Positive Topline Results from Phase 2/3 Fasinumab Study in Patients with Osteoarthritis Pain

05/02/16

TARRYTOWN, N.Y., May 2, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from a placebo-controlled Phase 2/3 study evaluating fasinumab in patients with moderate-to-severe osteoarthritis pain of the hip or knee who have a history of inadequ...

Read more

Upcoming Events

Regeneron Pharmaceuticals Q1 2016 Earnings Conference Call

05/05/16 at 8:30 AM

View Event

Bank of America Merrill Lynch Healthcare Conference

05/10/16 at 8:00 AM PT

View Event




Close
Form content here please :)